Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients With First-Episode Psychosis and Low Risk of Self-harm or Aggression: A Secondary Analysis of a Randomized Clinical Trial.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 09 2021
Historique:
pubmed: 24 6 2021
medline: 19 1 2022
entrez: 23 6 2021
Statut: ppublish

Résumé

Altered functional connectivity (FC) is a common finding in resting-state functional magnetic resonance imaging (rs-fMRI) studies of people with psychosis, yet how FC disturbances evolve in the early stages of illness, and how antipsychotic treatment influences these disturbances, remains unknown. To investigate longitudinal FC changes in antipsychotic-naive and antipsychotic-treated patients with first-episode psychosis (FEP). This secondary analysis of a triple-blind, randomized clinical trial was conducted over a 5-year recruitment period between April 2008 and December 2016 with 59 antipsychotic-naive patients with FEP receiving either a second-generation antipsychotic or a placebo pill over a treatment period of 6 months. Participants were required to have low suicidality and aggression, to have a duration of untreated psychosis of less than 6 months, and to be living in stable accommodations with social support. Both FEP groups received intensive psychosocial therapy. A healthy control group was also recruited. Participants completed rs-fMRI scans at baseline, 3 months, and 12 months. Data were analyzed from May 2019 to August 2020. Resting-state functional MRI was used to probe brain FC. Patients received either a second-generation antipsychotic or a matched placebo tablet. Both patient groups received a manualized psychosocial intervention. The primary outcomes of this analysis were to investigate (1) FC differences between patients and controls at baseline; (2) FC changes in medicated and unmedicated patients between baseline and 3 months; and (3) associations between longitudinal FC changes and clinical outcomes. An additional aim was to investigate long-term FC changes at 12 months after baseline. These outcomes were not preregistered. Data were analyzed for 59 patients (antipsychotic medication plus psychosocial treatment: 28 [47.5%]; mean [SD] age, 19.5 [3.0] years; 15 men [53.6%]; placebo plus psychosocial treatment: 31 [52.5%]; mean [SD] age, 18.8 [2.7]; 16 men [51.6%]) and 27 control individuals (mean [SD] age, 21.9 [1.9] years). At baseline, patients showed widespread functional dysconnectivity compared with controls, with reductions predominantly affecting interactions between the default mode network, limbic systems, and the rest of the brain. From baseline to 3 months, patients receiving placebo showed increased FC principally within the same systems; some of these changes correlated with improved clinical outcomes (canonical correlation analysis R = 0.901; familywise error-corrected P = .005). Antipsychotic exposure was associated with increased FC primarily between the thalamus and the rest of the brain. In this secondary analysis of a clinical trial, antipsychotic-naive patients with FEP showed widespread functional dysconnectivity at baseline, followed by an early normalization of default mode network and cortical limbic dysfunction in patients receiving placebo and psychosocial intervention. Antipsychotic exposure was associated with FC changes concentrated on thalamocortical networks. ACTRN12607000608460.

Identifiants

pubmed: 34160595
pii: 2781373
doi: 10.1001/jamapsychiatry.2021.1422
pmc: PMC8223142
doi:

Substances chimiques

Antipsychotic Agents 0

Banques de données

ANZCTR
['ACTRN12607000608460']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

994-1004

Auteurs

Sidhant Chopra (S)

Turner Institute for Brain and Mental Health, Monash University School of Psychological Sciences, Clayton, Victoria, Australia.
Monash Biomedical Imaging, Monash University, Clayton, Victoria, Australia.

Shona M Francey (SM)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Brian O'Donoghue (B)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Kristina Sabaroedin (K)

Turner Institute for Brain and Mental Health, Monash University School of Psychological Sciences, Clayton, Victoria, Australia.
Monash Biomedical Imaging, Monash University, Clayton, Victoria, Australia.

Aurina Arnatkeviciute (A)

Turner Institute for Brain and Mental Health, Monash University School of Psychological Sciences, Clayton, Victoria, Australia.

Vanessa Cropley (V)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne & Melbourne Health, Melbourne, Victoria, Australia.

Barnaby Nelson (B)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Jessica Graham (J)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Lara Baldwin (L)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Steven Tahtalian (S)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne & Melbourne Health, Melbourne, Victoria, Australia.

Hok Pan Yuen (HP)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Kelly Allott (K)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Mario Alvarez-Jimenez (M)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Susy Harrigan (S)

Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Department of Social Work, Monash University, Caulfield, Victoria, Australia.

Christos Pantelis (C)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne & Melbourne Health, Melbourne, Victoria, Australia.

Stephen J Wood (SJ)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
University of Birmingham School of Psychology, Edgbaston, United Kingdom.

Patrick McGorry (P)

Orygen, Parkville, Victoria, Australia.
Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.

Alex Fornito (A)

Turner Institute for Brain and Mental Health, Monash University School of Psychological Sciences, Clayton, Victoria, Australia.
Monash Biomedical Imaging, Monash University, Clayton, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH